Natriuretic Peptide Testing in Clinical Medicine
- 1 September 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Cardiology in Review
- Vol. 16 (5) , 240-249
Abstract
Since the discovery of atrial natriuretic factor in 1981 by de Bold et al, there has been tremendous progress in our understanding of natriuretic peptides (NPs). Recently, testing for brain-type NP (BNP) and its amino terminal cleavage equivalent (NT-proBNP) has been rapidly adopted in clinical medicine for numerous indications, including the diagnosis and exclusion of heart failure (HF). In this regard, logical application of BNP or NT-proBNP testing may not only reduce healthcare costs but also potentially reduce adverse clinical outcomes. With respect to this fact, the potential importance of the concentration of the NPs for prognosis and the response of BNP or NT-proBNP to therapeutic intervention in terms of clinical events has been demonstrated. On the basis of these observations it is reasonable to expect that concentrations of these peptides might be useful for the management of patients with HF, acting as a gauge of therapeutic accuracy and/or stability of disease. Besides HF, the prognostic utility of NPs has been explored in other settings, particularly in ischemic heart disease and those conditions that lead to right ventricular dysfunction.Keywords
This publication has 119 references indexed in Scilit:
- N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP), Cardiovascular Events, and Mortality in Patients With Stable Coronary Heart DiseaseJAMA, 2007
- Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: The role of biologic variation in the interpretation of resultsAmerican Heart Journal, 2006
- Management of elderly patients with congestive heart failure—Design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)American Heart Journal, 2006
- Testing new targets of therapy in advanced heart failure: The design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trialAmerican Heart Journal, 2005
- Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failureAmerican Heart Journal, 2005
- Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudyAmerican Heart Journal, 2005
- Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failureAmerican Heart Journal, 2003
- Brain natriuretic peptide-32: N-terminal six amino acid extended form of brain natriuretic peptide identified in porcine brainBiochemical and Biophysical Research Communications, 1988
- Biventricular performance during volume loading in patients with early septic shock, with emphasis on the right ventricle: A combined hemodynamic and radionuclide studyAmerican Heart Journal, 1988
- A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in ratsLife Sciences, 1981